Abstract: Objective: To investigate the clinical efficacy of autologous bone marrow concentrate combined with growth factor in the treatment of tibial and fibular non union. Method: A total of 58 patients with tibiofibular non union admitted to our hospital from January 2018 to May 2022 were selected, including 40 males and 18 females. Age range from 30 to 55 years old, with a median age of 42.5 years; 30 cases on the left and 28 cases on the right. In 58 patients, 100 ml venous blood was drawn from the elbow vein to prepare autologous growth factor. Inject approximately 4 ml of autologous growth factor three days before the injection of autologous bone marrow concentrate. After successful anesthesia, approximately 30 ml of autologous bone marrow was extracted from the patient''s posterior superior iliac spine using a heparinized sterile needle tube. After density gradient centrifugation, approximately 3 ml of autologous bone marrow concentrate was obtained and sent to the operating room for injection. Perform another injection of autologous growth factor on the third day after injection. X-ray examinations were conducted at the 2nd, 4th, 6th, and 8th month follow-up after autologous bone marrow concentrate combined with growth factor treatment to observe the healing of tibia and fibula, and evaluate the efficacy of autologous growth factor combined with bone marrow concentrate in the treatment of tibia and fibula non union based on the evaluation criteria of bone callus and fracture line imaging. Result: All 58 patients had complete follow-up data, with a follow-up period of 2-8 months. Among them, 56 patients met the clinical fracture healing standards, with a healing rate of 96.6%. The healing time of bone non union in 56 patients was 2-6 months, with an average of 3.2 months. Conclusion: The combination of autologous bone marrow concentrate and growth factor has good clinical efficacy in the treatment of tibial and fibular non union, and is worthy of clinical promotion and application.